Proteome Sciences PLC Appointment of Chief Executive Officer (8237Y)
14 Setembro 2020 - 3:00AM
UK Regulatory
TIDMPRM
RNS Number : 8237Y
Proteome Sciences PLC
14 September 2020
14 September 2020
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Appointment of Chief Executive Officer
The Board of Proteome Sciences plc is pleased to announce that
Dr. Mariola Söhngen has been appointed as a director and Chief
Executive Officer and she will take up the position on September
15th, 2020. Dr Ian Pike remains a director of the Company as Chief
Scientific Officer, having also fulfilled the role of Interim Chief
Executive Officer until Dr Söhngen's appointment.
Dr. Söhngen has established a strong and successful career in
the pharmaceutical industry both in the US and Europe. She was a
co-founder of Paion AG which developed a clinical-stage asset for
the treatment of stroke and subsequently delivered a novel
anaesthetic that received FDA approval earlier this year. Dr.
Söhngen was instrumental in the acquisition of UK listed CeNeS
Pharmaceuticals plc by Paion AG. Dr. Söhngen has also held roles as
CEO at Mologen AG and Convert Pharmaceuticals and most recently ran
a pharmaceutical consultancy with a strong focus on supporting
Chinese companies and investors trying to enter the European
pharmaceuticals research and development market.
Proteome Sciences Chairman Christopher Pearce commented "The
Board is delighted to appoint Dr, Mariola Söhngen as our new CEO
where she will build on the strong foundations that have already
been established. Mariola's time as Chief Medical Officer at Paion
together with her international experience and network will bring
major benefits to our business as we look to engage more broadly
with new and existing clients in the US, Europe and to address the
rapidly growing Asian markets."
Commenting on her appointment, Dr. Söhngen said "I am very much
looking forward to working with the highly respected and committed
team at Proteome Sciences. The company has established a unique
position in Precision Medicine through its specialist services
business and the range of TMT(R) and TMTpro(TM) chemical tags sold
globally by Thermo Scientific. I am excited to work with the board
to expand commercial activities and continue to develop the
corporate strategy. From my involvement in stroke at Paion, I
arrive at the company highly impressed with the quality of the
Proteome Sciences' technology in particular the biomarker discovery
capabilities in Precision Medicine and Diagnostics which are of
ever-increasing importance and value in these challenging times. As
CEO of Proteome Sciences I look forward to applying the broad
experience gained from my previous interactions with a wide range
of pharmaceutical companies to strengthen Proteome Sciences'
position in Precision Medicine and to drive shareholder value."
Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Dr.
Mariola Gabriela Söhngen (aged 59) has held the following
directorships or partnerships in the past five years:
Current Previous
Dres. Söhngen PAION AG
Beteiligungs GmbH PAION Deutschland
GmbH
PAION Holdings UK
Limited
PAION UK Limited
THERASCI Limited
Vita 34 AG
Mologen AG
Convert Pharmaceuticals
SA
-------------------------
For further information:
Proteome Sciences plc
Dr Ian Pike, Interim Chief Executive Tel: +44 (0)20 7043 2116
Officer
Richard Dennis, Chief Commercial Officer
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter (Corporate Tel: +44 (0) 20 3328 5656
Finance)
Tony Quirke (Sales)
About Proteome Sciences plc. ( www.proteomics.com )
Proteome Sciences plc is a specialist provider of contract
proteomics services to enable drug discovery, development and
biomarker identification, and employs proprietary workflows for the
optimum analysis of tissues, cells and body fluids. SysQuant(R) and
TMT(R) MS2 are unbiased methods for identifying and contextualising
new targets and defining mechanisms of biological activity, while
analysis using Super-Depletion and TMTcalibrator(TM) provides
access to over 8,500 circulating plasma proteins for the discovery
of disease-related biomarkers. Targeted assay development using
mass spectrometry delivers high sensitivity, interference-free
biomarker analyses in situations where standard ELISA assays are
not available.
The Company has its headquarters in London, UK, with laboratory
facilities in Frankfurt, Germany.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADZGMLGFGGGZZ
(END) Dow Jones Newswires
September 14, 2020 02:00 ET (06:00 GMT)
Proteome Sciences (AQSE:PRM.GB)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Proteome Sciences (AQSE:PRM.GB)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
